BioInvent International AB

Check out this sunshine story of how researchers at BioInvent International AB and University of Southampton came to collaborate on an immune receptor controlling antibody drug resistance and develop two therapeutic antibodies with promising activity in human cancer patients. #cancerimmunotherapy #immunology #immunecheckpoint #firstinclass #FcgRIIb #biotech #academia #collaboration

BioInvent International AB har utsett Ashley Robinson till Senior Vice President Strategy & Finance. Robinson kommer att spela en central roll i att stärka bolagets strategiska positionering och expandera närvaron i USA, en nyckelmarknad för BioInvents tillväxtambitioner. BioStock sökte Robinson för en kommentar.

This morning we announced that the first patient has been enrolled in the Phase 1b/2a study of our second anti-FcyRIIB antibody BI-1607 in combination with ipilimumab and KEYTRUDA (pembrolizumab) in patients with unresectable or metastatic melanoma. BI-1607 is an engineered antibody that can be viewed as a platform to enhance efficacy and overcome resistance to existing cancer treatments, such as targeted monoclonal antibodies and immune checkpoint inhibitors. In December 2023, BioInvent presented first clinical data from the Phase 1 dose escalation study evaluating BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors. The data demonstrated that the treatment was well tolerated, and no serious adverse events related to BI-1607 were observed. Stabilization of the disease was observed in 7 patients. Previously in 2021, BioInvent announced preclinical proof-of-concept data showing the ability of BI-1607 to overcome resistance to CTLA-4-based therapy. "The early data delivered so far by our BI-1607 program have been highly promising and we are very pleased to be advancing the asset's development with this new study," said Martin Welschof, Chief Executive Officer of BioInvent. "We have shown BI-1607 to be safe and well tolerated with signs of early clinical activity in Phase 1 evaluation in combination with trastuzumab. Additionally, our preclinical data also indicate that a regimen including BI-1607 could allow the use of lower doses of ipilimumab, potentially achieving increased tolerability and higher efficacy. We are looking forward to exploring the huge potential of this combination further and preliminary data from the study expected next year", said Martin Welschof, CEO of BioInvent. News summary: ·    Study to evaluate safety and anti-tumoral activity of anti-FcgRIIB antibody BI-1607 with anti-CTLA-4: ipilimumab, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA)( anti-PD-1 therapy, KEYTRUDA® (pembrolizumab); initial data expected in H2 2025 ·    Data from Phase 1 study in combination with trastuzumab previously demonstrated BI-1607 is safe, well tolerated and achieves full receptor occupancy during the treatment interval at several dose levels; preclinical data show BI-1607 enables lower anti-CTLA-4 dosing with improved survival ·    Clinical supply agreement for KEYTRUDA® in place with MSD #immunooncology #immunotherapy #antibodytherapeutics #biotechnology #lifescience

Today we announced the appointment of Ashley Robinson as SVP Strategy & Finance. In this role, Mr. Robinson will spearhead efforts to strengthen BioInvent’s presence and strategy in the US. "We are delighted to welcome Ashley as our SVP Strategy & Finance and we are looking forward to benefiting from his experience and expertise in healthcare financing and biotechnology consulting," said Martin Welschof, Chief Executive Officer of BioInvent. "Ashley will be based in the US where we are planning to expand BioInvent's presence as part of the strategic development of our company and the continued advancement of our unique immuno-oncology pipeline." Ashley Robinson is an accomplished biotechnology business leader and joins BioInvent with 25 years in capital markets and corporate strategy experience. Most recently, he served as Managing Director at LifeSci Advisors, where he established a Life Sci office in Boston, advising key clients in the healthcare sector. Prior roles have been healthcare product specialist, sector head at Guggenheim Securities, Managing Director and Senior Partner at Leerink Partners, Vice President at Lehman Brothers in the ECM division. "It is a great privilege to become part of the BioInvent team and to join the efforts in the discovery and development of new and innovative cancer therapies," said Ashley Robinson, SVP Strategy & Finance of BioInvent. "The company is in a strong position with a robust and highly differentiated clinical pipeline, and I am excited to be part of this new phase of growth and development." #immunooncology #immunotherapy #antibodytherapeutics #biotechnology #lifescience

It’s been great presenting, discussing, and chairing sessions at #PEGSeurope. Sharing great science, recognizing the transformative progress we have made, and communicating hypothesis that will translate into the next breakthroughs for patients (and their families), is humbling and energizing. Thank you, fellow data-driven colleagues! See you next year in sunny Lisbon #Cancerimmunotherapy #Firstinclass #Immunology #TNFR2 #FcgRIIB #Immunecheckpoint #Bioinvent

𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞: Pareto Securities Biotech Analyst Dan Akschuti shares his thoughts on #BIOEurope and discusses recent company successes in the Nordic region. He says there has been an upswing in investors looking at companies. Plus, his thoughts on BioInvent International AB, Oculis, and Camurus. Full video: https://lnkd.in/gPUYnkD6 BiotechTV's coverage of BIO-Europe 2024 is brought to you by Pareto Securities BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

Part of the BioInvent clinical team attended the HEMO 2024 conference in São Paulo in October 2024. HEMO is the Brazilian Congress of Hematology, Hemotherapy, and Cellular Therapy and the 3rd largest conference in the world, in this field of therapy.   During the congress, our CMO Andres McAllister, MD PhD, and the BioInvent team met with investigators and potential new investigators for the ongoing clinical Phase 2 study of BI-1206 for the treatment of NHL. In conjunction to the meeting, the team also visited some of the hospitals, including A.C. Camargo Cancer Center, São Paulo, that is participating in the ongoing study.   On October 31st, 2024, BioInvent was pleased to present continued positive new data from the study of subcutaneous BI-1206 in combination with rituximab in NHL patients, showing one new complete response (CR), totaling two, one new partial response (PR), totaling three and two more patients with stable disease (SD) totaling three.   Another important recent milestone in the development of BI-1206 is the enrolment of the first patient in the triple combination arm of the Phase 1/2a study of BI-1206. The combination of BI-1206 and rituximab has already demonstrated promising signs of clinical efficacy with a favorable safety profile, and we have a strong rationale supporting the concept that the addition of Calquence® (acalabrutinib) will increase response rates even further. In this study, we will use the subcutaneous formulation of BI-1206 which will provide significant more convenience and enhanced tolerability to the treatment. #immunooncology #immunotherapy #biotechnology #antibodytherapeutics

Last week, our CSO Björn Frendéus participated in an online webinar on the topic "Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as a “Next Big Thing” in Cancer Immunotherapy" organized by Lumanity. Don't miss! Register and listen through the link below. https://lnkd.in/dNmVdARk #immunooncology #immunotherapy #biotechnology #lifescience

“Progress to date brings the company one step closer to addressing the needs for new treatment solutions for patients. As part of our Q3 report, we are today pleased to present continued positive data from the Phase 1 part of the study with BI-1206 as a subcutaneous (SC) formulation for the treatment of NHL. We now have another complete response (CR) and another partial response (PR), adding to the already promising response levels (1 CR, 2 PR) presented at EHA in June this year. In addition, the recent efficacy data in CTCL and solid tumors with BI-1808 administered as monotherapy are compelling.” - Martin Welschof CEO of BioInvent commented on the interim report. EVENTS IN THE THIRD QUARTER • (R) Additional positive efficacy data with single agent BI-1808 from the Phase 2a anti-TNFR2 program; CTCL cohort showed three PR and one SD out of four evaluable patients. • First patient enrolled in Phase 2a triple combination arm of BI-1206, rituximab and Calquence® for the treatment of non-Hodgkin’s lymphoma. The subcutaneous formulation (SC) of BI-1206 selected. • Notice of Allowance received from USPTO for BI-1910 patent application. • New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1607, the company’s second anti-FcyRIIB antibody in combination with KEYTRUDA® (pembrolizumab) and ipilimumab. • Two programs presented at ESMO 2024: » Status update for the ongoing Phase 1/2a study with the company’s second anti-TNFR2 antibody BI-1910. » Results from the ongoing Phase 1/2a trial with the oncolytic virus BT-001 armed with BioInvent’s anti-CTLA-4 antibody, showing promising antitumor activity in patients with solid tumors that had failed previous treatments. EVENTS AFTER THE END OF THE PERIOD • Additional positive data from the Phase 1 part of the study with BI-1206 as a SC formulation for the treatment of NHL. Clinical responses adding to a total of two CRs, three PRs and three SDs out of nine evaluable patients. (R)= Regulatory event The complete interim report is available for download below and on the company’s website under Financial reports. INVITATION TO PRESENTATION OF THE INTERIM REPORT JAN – SEP 2024 BioInvent’s CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When: Thursday October 31, 2024, at 5:00 pm CET If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. https://lnkd.in/dfGXxYxf If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. https://lnkd.in/dw7WhqEd The conference call will be made available on the company website after the call.